HARG IT - Healthy Aging Research Group

HARG

HARG is an Italian company specialized in researching, developing, and commercializing foods for people with swallowing and chewing difficulties. Recognized as a Benefit Corporation, they offer a significant innovation in the field of nutraceuticals, validated in collaboration with renowned academic institutions such as the Department of Health Sciences at the University of Genova. Their solution addresses the challenges related to nutrition for dysphagic patients, providing meals based on natural ingredients enriched with nutrients to ensure specific and measured nutritional values, fully complying with international guidelines.

Early detection and treatment of malnutrition significantly improve the general conditions and life quality of individuals. HARG's diverse "Dysphameal Menu" allows for the administration of highly important nutritional values in small volumes (1900Kcal and 60g proteins), unattainable through regular blended diets, often necessitating nutritional supplementation or integration.

Their feeding protocol is based on monitoring the outcomes of the diet on patients, including nutrition-related blood values and pressure ulcer development. Consistent nutritional intake can eliminate the need for supplementation in patients at nutritional risk or experiencing weight loss for various reasons.

Dysphameal meals are easy and quick to prepare, highly palatable, and designed to stimulate the sense of smell and taste, rediscovering the pleasure of consuming real food. They are also low in simple sugars, suitable for diabetic patients, and have a high water content to satisfy daily water intake, often challenging to administer through diet alone.

HARG was founded in 2017 and operates in the industries of Food and Beverage, Health Care, and Nutrition. Their headquarters are in Italy. In the latest recorded investment round on 01 February 2023, they secured a €2.50M Venture Round with participation from a|impact - Avanzi Etica SICAF EuVECA S.p.A., Gruppo Brixia, and CDP Venture Capital.